Clinical Report: Combo Therapy for Psoriasis With Obesity
Overview
In the TOGETHER-PsO trial, ixekizumab combined with tirzepatide demonstrated superior efficacy in achieving both complete skin clearance and at least 10% weight loss in patients with moderate-to-severe plaque psoriasis and obesity. At 36 weeks, 27% of patients on the combination therapy achieved both outcomes compared to 6% on ixekizumab alone.
Background
Psoriasis is a chronic inflammatory skin condition that significantly impacts quality of life, and obesity is a common comorbidity that complicates its management. The integration of weight management strategies into psoriasis treatment is increasingly recognized as essential for improving patient outcomes. Recent studies suggest that effective weight loss can enhance the efficacy of psoriasis therapies, highlighting the need for combined treatment approaches.
Data Highlights
| Outcome | Ixekizumab + Tirzepatide | Ixekizumab Alone |
|---|---|---|
| Complete Skin Clearance | 27% | 6% |
| PASI 100 Achievement | 41% | 29% |
| Weight Loss (≥10%) | 27% | 6% |
Key Findings
- 27% of patients on ixekizumab plus tirzepatide achieved complete skin clearance at 36 weeks.
- Only 6% of patients achieved the same outcome with ixekizumab monotherapy.
- 41% of patients in the combination group reached PASI 100 compared to 29% in the monotherapy group.
- The study enrolled 274 patients with a mean BMI greater than 39 kg/m².
- Adverse events were generally mild to moderate, including nausea, diarrhea, injection site reactions, and others, with specific frequencies to be detailed in future publications.
Clinical Implications
The findings support the use of combination therapy with ixekizumab and tirzepatide as a viable option for patients with psoriasis and obesity, potentially leading to improved treatment outcomes. Clinicians should consider integrated weight management strategies alongside dermatologic therapies to optimize patient care while monitoring for adverse events.
Conclusion
The TOGETHER-PsO trial highlights the potential benefits of combining ixekizumab with tirzepatide in treating psoriasis in obese patients, suggesting a promising avenue for enhancing therapeutic efficacy compared to existing treatment options.
Related Resources & Content
- Eli Lilly and Company, Press Release, 2023 -- Combo Therapy for Psoriasis With Obesity
- conexiant — UVB and Psoriasis: More Than Immunosuppression
- The New Gastroenterologist — Strategies for Managing Weight in Gastroenterology Practice
- conexiant — Dual Therapy Boosts Weight Loss in Trial
- Blood Cancer Journal — Influence of Body Weight and Obesity on Treatment Outcomes in Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Axicabtagene Ciloleucel
- UVB and Psoriasis: More Than Immunosuppression
- Strategies for Managing Weight in Gastroenterology Practice
- Dual Therapy Boosts Weight Loss in Trial
- Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
- Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis
- NPF Medical Board Issues GLP-1 Primer for Dermatologists
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
